2 results
Approved WMOCompleted
2.1.1 Primary Objective:To evaluate the difference in the rates of graded pulmonary exacerbations in patients with bronchiectasis treated with inhaled mannitol compared with placebo control2.1.2 Secondary Objectives:EfficacyTo evaluate the…
Approved WMORecruiting
The main objective of PD0053 is to provide POC for the efficacy of the ASYN misfolding inhibitor UCB0599 in reducing disease progression in study participants with early-stage PD, and to instruct later stage development. The ultimate goal is to…